Biogen, Inc. (NQ: BIIB )

291.43 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'

February 06, 2023

Via Benzinga

Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Biogen Inc.

Via Globe NewsWire

Is Biogen Stock a Buy Now?

January 26, 2023

Its new drug might succeed where the company faltered in 2021.

Via The Motley Fool

Where Biogen Stands With Analysts

January 24, 2023

Via Benzinga

FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data

January 20, 2023

Via Benzinga

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023

February 01, 2023

For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.

Via InvestorPlace

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today

January 19, 2023

Via Benzinga

Cassava Sciences Stock Undervalued with Its $124 Price Target?

January 30, 2023

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

Via MarketBeat

Exposures Product Safety

Lecanemab Receives Priority Review Status in Japan

January 29, 2023

From Biogen Inc.

Via Globe NewsWire

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

January 26, 2023

From Biogen Inc.

Via Globe NewsWire

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

January 25, 2023

Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.

Via The Motley Fool

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

January 20, 2023

The company will need to complete its confirmatory study before asking for approval.

Via Investor's Business Daily

Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss

January 20, 2023

U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions. What Happened: Traders may have to contend with Fed speeches and housing market...

Via Benzinga

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

January 19, 2023

The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.

Via The Motley Fool

If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today

January 19, 2023

The stock hasn't been a great investment in recent years, but there's hope for a brighter future.

Via The Motley Fool

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen

January 18, 2023

Via Benzinga

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich

January 17, 2023

The fountain of youth might not be a myth in the future.

Via The Motley Fool

Elliott Wave Technical Analysis: Biogen Inc.

January 13, 2023

We are looking for further downside into wave C which could take us back to the area of wave 4.

Via Talk Markets

1 Hot Growth Stock to Buy Now, and 1 to Avoid

January 11, 2023

One company is gearing up for further growth while the other stumbles over itself.

Via The Motley Fool

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish

January 11, 2023

2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.

Via Talk Markets

Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?

January 10, 2023

There's more to the story with Biogen after receiving good news for Leqembi.

Via The Motley Fool

Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill

January 07, 2023

Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.

Via Benzinga

Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug

January 06, 2023

Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.

Via Benzinga

SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday

January 06, 2023

Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to

Via Benzinga

FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway

January 06, 2023

Via Benzinga

Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?

January 06, 2023

Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.